厚朴健胃灵片治疗慢性非萎缩性胃炎:双盲非劣效随机对照试验
该II期双盲随机平行对照试验在巴基斯坦单中心纳入240例伴糜烂的慢性非萎缩性胃炎患者,按1:1随机分为厚朴健胃灵片组和奥美拉唑组,疗程28天。结果显示两组临床改善率分别为91.1%和91.0%,组间差异无统计学意义(p=0.9824),且厚朴健胃灵片安全性良好,非劣效于奥美拉唑。
要点
- 厚朴健胃灵片治疗慢性非萎缩性胃炎临床改善率达91.1%,非劣效于奥美拉唑。
- 两组幽门螺杆菌转阴率分别为70.1%和71.8%,差异无统计学意义(p=0.8125)。
- 厚朴健胃灵片安全性良好,未观察到明显不良反应或心电图、生命体征异常。
核心结论
- 厚朴健胃灵片治疗轻中度慢性非萎缩性胃炎非劣效于奥美拉唑,且安全性良好。
研究设计与样本
- 共纳入240例经病理活检和胃镜确认伴糜烂的慢性非萎缩性胃炎患者,按1:1随机分为对照组(奥美拉唑,n=120)和治疗组(厚朴健胃灵片,n=120)。
主要发现
- 治疗组临床改善率为91.1%,对照组为91.0%,组间差异无统计学意义(p=0.9824;95%CI:-0.0781~0.0798)。
- 治疗组幽门螺杆菌转阴率为70.1%,对照组为71.8%,差异无统计学意义(p=0.8125)。
- 两组胃痛消失时间(p=0.1860)和缓解率(p=0.5784)差异无统计学意义,但对照组胃肠道不适缓解期更快(p=0.0430)。
- 对照组仅1例出现轻度至中度不良事件(上腹痛和消化不良)。
关键数值与推荐
- 有效性非劣效界值为-0.15,两组有效率差值的95%CI下限为-0.0781,大于-0.15,结论为非劣效。
- 治疗组用法:厚朴健胃灵片(0.38g/片)每次4片,每日3次,早餐前加服1片奥美拉唑安慰剂,疗程28天。
- 对照组用法:奥美拉唑肠溶片(20mg/片)早餐前1片,每日3次加服4片厚朴健胃灵片安慰剂,疗程28天。
临床怎么用
- 厚朴健胃灵片可作为轻中度慢性非萎缩性胃炎伴糜烂患者的治疗选择之一。
- 用药期间需关注胃肠道不适缓解速度可能略慢于质子泵抑制剂。
- 治疗过程中应监测不良反应及心电图、生命体征和实验室指标。
局限性
- 单中心研究,样本量240例,结论外推需谨慎。
- 疗程仅28天,缺乏长期疗效和安全性数据。
- 研究人群为巴基斯坦患者,人种差异可能影响结果普适性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Common symptoms of Chronic Non-atrophic Gastritis (CNAG) include nausea, stomach distension, and abdominal pain. The Houtou Jianweiling Tablet (HTJWT) is a chinese patent medicine (CN1368229A) and it has been used clinically for more than 20 years with proven clinical efficacy in treating CNAG, prompted us to establish the clinical efficacy and safety of HTJWT on patients with mild to moderate CNAG symptoms in Pakistani population. Methods: This phase II, double-blind, randomized, parallel-controlled trial was conducted in a single center between November 2022 and February 2023 in Pakistan. In a ratio of 1:1, total 240 CNAG patients with erosion identified by pathological biopsy and gastroscopy were randomly assigned to control (Omeprazole) group (n = 120) and the treatment (HTJWT) group (n = 120). Patients in the treatment group received orally four HTJWT (0.38g/tablet), three times a day and one placebo of Omeprazole enteric-coated tablet prior to breakfast, daily. On the other hand, patients in the control group received one Omeprazole enteric-coated tablet (20 mg/tablet) prior to breakfast and four placebo of HTJWT, thrice a day. The patients consumed the investigated drugs (i.e., treatment and control) treatment regimen was followed for a duration of 28 days. The safety of the patients were evaluated through adverse events, serious adverse events and laboratory tests such as blood biochemistry, urine analysis, liver and renal function tests. Vital signs like; blood pressure, pulse rate, body temperature, respiratory rate for all the patients were recorded. The cardiac status of the patients were assessed through electrocardiogram (ECG). The primary efficacy indicators were the improvement rate of gastric distention and gastralgia as the main clinical symptoms. Secondary indicators were visual analogue score (VAS); improvement rate of secondary clinical symptoms and signs; improvement rate of total clinical signs and symptoms; the disappearance/remission rate of Gastric pain and, remission/disappearance time of gastric distension; and the negative conversion rate of Helicobacter pylori (H. pylori). The outcomes among each group were compared using the chi-square test. Results: Patients in both groups had good drug compliance (80%-120%), and there was no statistically significant difference in the patients' baseline characteristics. The clinical improvement rate was found to be 91.1% in the treatment group and 91.0% in the control group with negligible variation among the two groups (p = 0.9824; 95% confidence interval: -0.0781-0.0798). Similarly, hardly no difference was found in the negative conversion rate of H. pylori between the treatment group and the control group (i.e., 70.1% and 71.8% respectively, p = 0.8125). There were no significant differences in respiratory rate, vital signs, blood pressure, laboratory results for blood biochemistry, urine analysis, liver and renal function tests between the two groups. The ECG assessment carried out for the treatment and control group revealed no considerable difference. Margin variation in the disappearance time of gastric pain (p = 0.1860) and remission rate (p = 0.5784) between the two groups were observed. The control group exhibited a faster remission period for gastrointestinal discomfort indications as compared to treatment group (p = 0.0430). Only one patient in the control group experienced mild to moderate adverse events, namely,; epigastric pain and dyspepsia. The results were consistent with the intention-to-treat and per-protocol analysis that included patients who were 100% compliant to the assigned therapy. Conclusion: The lower limit of confidence interval (CI, 95%) for the differences in the effective rate between the treatment and the control groups was found to be -0.0781 which is greater than -0.15, hence the treatment group is non-inferior to the control group. The therapeutic dosage used in the trial and treatment period did not cause any significant adverse event, and there were no obvious changes in the ECG profile, vital signs and biochemistry of the patients. Based on the clinical efficacy evaluation and reported adverse events, it can be concluded that the HTJWT is a safe and effective traditional chinese medicine for the treatment of patients suffering from chronic non-atrophic gastritis with mild to moderate symptoms. Clinical Trial Registration: [www.clinicaltrials.gov], identifier [NCT04672018].
引用
- Shah MR, Fatima S, Khan SN, et al. The safety and efficacy of Houtou Jianweiling tablet in patients with chronic non-atrophic gastritis: a double-blind, non-inferiority, randomized controlled trial. Front Pharmacol. 2024. PMID: 38440179. doi:10.3389/fphar.2024.1293272
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。